Cardlytics Inc (CDLX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.28 is considered Undervalued compared with the five-year average of -9.30. The fair price of Cardlytics Inc (CDLX) is between 3.02 to 3.53 according to relative valuation method. Compared to the current price of 0.83 USD , Cardlytics Inc By Undervalued By 72.58%.

Relative Value

Fair Zone

3.02-3.53

Current Price：0.83

72.58%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cardlytics Inc (CDLX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cardlytics Inc (CDLX) has a current Price-to-Book (P/B) ratio of -12.81. Compared to its 3-year average P/B ratio of -0.04, the current P/B ratio is approximately 31351.42% higher. Relative to its 5-year average P/B ratio of 1.38, the current P/B ratio is about -1027.41% higher. Cardlytics Inc (CDLX) has a Forward Free Cash Flow (FCF) yield of approximately -2.18%. Compared to its 3-year average FCF yield of -6.84%, the current FCF yield is approximately -68.16% lower. Relative to its 5-year average FCF yield of -7.13%, the current FCF yield is about -69.44% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CDLX competitors is 3.51, providing a benchmark for relative valuation. Cardlytics Inc Corp (CDLX.O) exhibits a P/S ratio of 0.28, which is -92.04% above the industry average. Given its robust revenue growth of -22.41%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CDLX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CDLX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CDLX currently overvalued or undervalued?

What is Cardlytics Inc (CDLX) fair value?

CDLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cardlytics Inc (CDLX) is between 3.02 to 3.53 according to relative valuation method.

How does CDLX's valuation metrics compare to the industry average?

The average P/S ratio for CDLX's competitors is 3.51, providing a benchmark for relative valuation. Cardlytics Inc Corp (CDLX) exhibits a P/S ratio of 0.28, which is -92.04% above the industry average. Given its robust revenue growth of -22.41%, this premium appears unsustainable.

What is the current P/B ratio for Cardlytics Inc (CDLX) as of Mar 03 2026?

As of Mar 03 2026, Cardlytics Inc (CDLX) has a P/B ratio of -12.81. This indicates that the market values CDLX at -12.81 times its book value.

What is the current FCF Yield for Cardlytics Inc (CDLX) as of Mar 03 2026?

As of Mar 03 2026, Cardlytics Inc (CDLX) has a FCF Yield of -2.18%. This means that for every dollar of Cardlytics Inc's market capitalization, the company generates -2.18 cents in free cash flow.

What is the current Forward P/E ratio for Cardlytics Inc (CDLX) as of Mar 03 2026?

As of Mar 03 2026, Cardlytics Inc (CDLX) has a Forward P/E ratio of -3.03. This means the market is willing to pay $-3.03 for every dollar of Cardlytics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cardlytics Inc (CDLX) as of Mar 03 2026?

As of Mar 03 2026, Cardlytics Inc (CDLX) has a Forward P/S ratio of 0.28. This means the market is valuing CDLX at $0.28 for every dollar of expected revenue over the next 12 months.

CDLX Valuation